Based on the key indicators related to Terns Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Terns Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, Terns Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Non Current Liabilities Total is likely to grow to about 4.1 M, while Total Assets are likely to drop about 203.2 M. Key indicators impacting Terns Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Terns Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Terns Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Terns Pharmaceuticals.
Terns Pharmaceuticals competes with Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, X4 Pharmaceuticals, and Mereo BioPharma. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Foreign Associate
UK
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Terns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Terns Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Terns Pharmaceuticals competition to find correlations between indicators driving Terns Pharmaceuticals's intrinsic value. More Info.
Terns Pharmaceuticals is rated fourth in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . At this time, Terns Pharmaceuticals' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Terns Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Terns Pharmaceuticals Systematic Risk
Terns Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Terns Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Terns Pharmaceuticals correlated with the market. If Beta is less than 0 Terns Pharmaceuticals generally moves in the opposite direction as compared to the market. If Terns Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Terns Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Terns Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Terns Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Terns Pharmaceuticals Thematic Clasifications
Terns Pharmaceuticals is part of Israel Wall Street investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing
This theme covers Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. Get More Thematic Ideas
Today, most investors in Terns Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Terns Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Terns Pharmaceuticals growth as a starting point in their analysis.
Terns Pharmaceuticals March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Terns Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Terns Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Terns Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Terns Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Terns Pharmaceuticals's daily price indicators and compare them against related drivers.
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.035
Return On Assets
(0.20)
Return On Equity
(0.30)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.